Log in to your Inderes Free account to see all free content on this page.

Chosa Oncology

0.89 SEK

0.00 %

Less than 1K followers

CHOSA

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Dividend

Investor consensus

0.00 %

+5.80 %

-1.22 %

-5.89 %

-28.48 %

+36.25 %

-26.06 %

-94.90 %

-92.91 %

Chosa Oncology is a Swedish-Danish biotechnology company that develops solutions for personalized cancer treatment with a focus on diagnostics and drug formulation. The company targets healthcare providers and research actors and works internationally with partners and clinical projects. Chosa Oncology was founded in 2022 and is headquartered in Lund, Sweden.

Market cap

78.55M SEK

Turnover

87.61 SEK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

27.5.

2026

General meeting '26

30.5.

2026

Interim report Q1'26

All

Press releases

ShowingAll content types

Press release4/27/2026, 11:00 AM

Chosa Oncology AB: CHOSA Oncology partners with Mount Sinai, New York to test biomarker guiding platin-immunotherapy in lung cancer

Regulatory press release4/24/2026, 12:30 PM

Notice of annual general meeting in Chosa Oncology AB

Press release4/24/2026, 10:26 AM

Chosa Oncology AB: CHOSA to present new Platin-DRP® data at ASCO 2026

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release3/26/2026, 12:00 PM

Chosa Oncology AB: CHOSA presents positive data on Platin-DRP® predicting overall survival in advanced NSCLC at the European Lung Cancer Congress 2026

Press release3/19/2026, 7:45 AM

Chosa Oncology AB: CHOSA to present Platin-DRP data predicting survival benefit from Carboplatin and Cisplatin in patients with advanced NSCLC from a Phase III study at the 2026 European Lung Cancer Congress

Press release1/23/2026, 7:33 AM

Chosa Oncology AB: Precision Oncology patent application targeting Platinum Response and Immunotherapy Synergy

Regulatory press release1/19/2026, 7:53 AM

Chosa Oncology AB: CHOSA Oncology AB resolves on a directed issue of units of initially approximately SEK 7.3 million

Regulatory press release12/11/2025, 1:12 PM

Chosa Oncology AB: CHOSA - The market now doubles for Platin-DRP®, which predicts overall survival in lung cancer patients based on NanoString data

Press release11/10/2025, 9:00 AM

Chosa Oncology AB: CHOSA - Platinum chemotherapy is the backbone of PD-1/PD-L1-based lung cancer therapy

Press release10/20/2025, 10:00 AM

Chosa Oncology AB: CHOSA's presented data on the carboplatin response predictor in breast cancer patients on the ESMO conference

Press release10/7/2025, 1:28 PM

Chosa Oncology AB: CHOSA Wins 2025 Jiangning International Entrepreneurship Contest (Greater Shanghai region), China

Regulatory press release9/30/2025, 11:03 AM

Chosa Oncology AB: CHOSA announces positive results from a clinical study in collaboration with ETOP/EORTC on platinum predictor in lung cancer

Press release8/8/2025, 6:00 AM

Chosa Oncology AB: CHOSA's presents data on the carboplatin response predictor in breast cancer patients on the annual ESMO conference

Regulatory press release8/1/2025, 12:29 PM

Chosa Oncology AB: Chosa Oncology's warrants of series TO 2 to be admitted to trading

Regulatory press release7/31/2025, 3:25 PM

Chosa Oncology AB: Chosa Oncology announces the last day of trading in BTU

Regulatory press release7/1/2025, 2:19 PM

Chosa Oncology AB: CHOSA extends the timeline for biopsy collection prior to publication from the SPLENDOUR study

Regulatory press release6/27/2025, 1:48 PM

Chosa Oncology AB: Chosa Oncology announces outcome in rights issue

Regulatory press release6/25/2025, 10:00 AM

Chosa Oncology AB: Last subscription day in Chosa's subscription period

Regulatory press release6/25/2025, 7:15 AM

Chosa Oncology AB: CHOSA files new patent application to predict which patients may benefit from platinum chemotherapy and immunotherapy

Regulatory press release6/13/2025, 11:42 AM

Bulletin from the annual general meeting on 13 June 2025 in Chosa Oncology AB

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.